fashion -WSS

fashion

author：Wikipedia 2025-10-02 18:05:38 - browse：166

WASHINGTON — Plenty of pharmaceutical executives have decried Democrats’ new drug pricing law as detrimental to the industry. But few are willing to say they may be willing to delay treatments for cancer patients if it means making more money.

Genentech CEO Alexander Hardy, in an interview with STAT, explained that in the world that existed prior to the Inflation Reduction Act’s passage last year, drugmakers were incentivized to get drugs on the market as fast as possible, regardless of which disease they would be approved to treat.

Now, he’s arguing that the law’s new Medicare negotiation program could encourage Genentech to slow-walk research on how a drug could treat diseases with smaller populations in favor of making sure diseases with larger patient populations are the first to market. That would mean the company would sell more medicines in the window before Medicare is allowed to negotiate prices, because the clock for when discounts can kick in is based off of when the drug first goes on the market.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： FDA approval of Sarepta Duchenne genetic therapy gives me hope
Next article： How faith leaders like me can help address America's obesity epidemic

focus

WSS

Novo Nordisk gets FDA approval to tout heart benefits of Wegovy

How to bring more disabled researchers into academia

What it’s like to watch children die of measles

Medical device trials still don't enroll enough women, study finds

How faith leaders like me can help address America's obesity epidemic

First medicine developed to treat MASH expected to be approved soon

focus

fashion

hotspot

Novavax promises a turnaround & Lilly roils the obesity market

Precocious puberty in girls comes with mental health risks

Supreme Court strikes down use of affirmative action

UnitedHealth quietly bought dozens of outpatient centers

Wildfire smoke exposes gaps in outdoor worker protections

Amylyx ALS drug failure raises questions and concerns

BioMarin wins approval for gene therapy to treat hemophilia A

How faith leaders like me can help address America's obesity epidemic

Hollywood unions extend contract negotiations for actors

Novo Nordisk obesity pill bests Wegovy in early trial

knowledge

Lilly's Alzheimer's drug donanemab backed by FDA advisers

Cancer thrives by mutating. But sometimes, a mutation leaves it vulnerable

Stephen Quake on the Chan Zuckerberg quest to conquer disease

Cheap, fast test for Zika and dengue could cost just $1

Readout Newsletter: Acadia, Eli Lilly, Madrigal Pharma updates

Curing rare childhood diseases will falter unless Congress steps up

knowledge

focus

focus

explore